Mizuho lowered the firm’s price target on Apellis (APLS) to $19 from $24 and keeps a Neutral rating on the shares following Q3 results. While Empaveli’s launch in C3G/IC-MPGN has gotten off to a “promising start,” Syfovre’s growth remains challenged, which is “more core to our thesis,” the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
- Apellis price target lowered to $45 from $50 at TD Cowen
- Apellis price target raised to $52 from $50 at Baird
- Apellis price target lowered to $45 from $52 at Citi
- Apellis price target lowered to $45 from $57 at H.C. Wainwright